Specialized Tumor Board Treatment Plan for Medulloblastoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Medulloblastoma+2 MoreSpecialized Tumor Board Treatment Plan - Other
Eligibility
12 - 39
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new way to treat medulloblastoma that is based on the molecular characteristics of each person's tumor.

Eligible Conditions
  • Medulloblastoma
  • Medulloblastoma Recurrent

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 2 years

Up to 2 years
Proportion of participants with Adverse Events
Up to 21 days
Median Time from tissue collection to issued treatment plan from the specialized tumor board

Trial Safety

Trial Design

1 Treatment Group

Individualized Treatment Recommendation
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Specialized Tumor Board Treatment Plan · No Placebo Group · N/A

Individualized Treatment Recommendation
Other
Experimental Group · 1 Intervention: Specialized Tumor Board Treatment Plan · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

Washington University School of MedicineOTHER
1,805 Previous Clinical Trials
2,278,693 Total Patients Enrolled
1 Trials studying Medulloblastoma
Ashion AnalyticsUNKNOWN
University of WashingtonOTHER
1,597 Previous Clinical Trials
1,569,139 Total Patients Enrolled
University of California, San FranciscoLead Sponsor
2,283 Previous Clinical Trials
11,577,660 Total Patients Enrolled
St. Baldrick's FoundationOTHER
18 Previous Clinical Trials
9,034 Total Patients Enrolled
1 Trials studying Medulloblastoma
137 Patients Enrolled for Medulloblastoma
Pacific Pediatric Neuro-Oncology ConsortiumOTHER
14 Previous Clinical Trials
785 Total Patients Enrolled
1 Trials studying Medulloblastoma
30 Patients Enrolled for Medulloblastoma
Sabine Mueller, MD, PhD, MASPrincipal InvestigatorUniversity of California, San Francisco
7 Previous Clinical Trials
224 Total Patients Enrolled
1 Trials studying Medulloblastoma
46 Patients Enrolled for Medulloblastoma
Margaret Shatara, MDStudy ChairWashington University School of Medicine
Joshua Rubin, MD, PhDStudy ChairWashington University School of Medicine
Megan Paul, MDStudy ChairRady Children's Hospital
Robert Wechsler-Reya, PhDStudy ChairSanford Burnham Prebs Medical Discovery Institute

Eligibility Criteria

Age 12 - 39 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The participants must have a disease that can be surgically accessed.
The person must have had medulloblastoma come back after they had one type of treatment before, either surgery with high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy
People who want to participate in this study must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy.
For biologic agents that have a prolonged half-life, the appropriate interval since last treatment should be discussed with the Study Chair prior to their use in the study.
People who want to participate in the study must have medulloblastoma that has come back after treatment.
People who are participating in this study must have received their last dose of anti-cancer chemotherapy that can suppress the bone marrow at least 3 weeks ago (6 weeks ago if the chemotherapy used is a nitrosourea).
Participants must have fully recovered from any toxicity related to the agent and received their last dose at least 7 days before enrolling in the study.
For agents that have known adverse events occurring more than 7 days after administration, the study chair should be consulted to determine how long this interval should be extended.
At least three half-lives must have elapsed prior to registration of participants in clinical trials using monoclonal antibodies
Bone marrow transplant: Participant must be at least 6 months since any type of bone marrow transplant (allogeneic or autologous) prior to registration